亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study

医学 危险系数 安慰剂 前列腺癌 内科学 恩扎鲁胺 人口 中期分析 无进展生存期 临床终点 肿瘤科 雄激素剥夺疗法 随机对照试验 置信区间 泌尿科 外科 化疗 癌症 病理 雄激素受体 替代医学 环境卫生
作者
Hirotsugu Uemura,Gaku Arai,Hiroji Uemura,Hiroyoshi Suzuki,Kazuyoshi Iijima,Kazuo Nishimura,Koji Fujii,Tomoyoshi Hatayama,Junya Aoyama,Kris Deprince,Angela Lopez-Gitlitz,Sharon McCarthy,Julie S. Larsen,Jinhui Li,Kim N.
出处
期刊:International Journal of Urology [Wiley]
卷期号:28 (3): 280-287 被引量:11
标识
DOI:10.1111/iju.14447
摘要

Objective To evaluate the efficacy and safety of apalutamide + androgen deprivation therapy versus androgen deprivation therapy alone in Japanese patients with metastatic castration‐sensitive prostate cancer from the phase 3, randomized, global TITAN study. Methods Men with metastatic castration‐sensitive prostate cancer randomly (1:1) received 240 mg apalutamide + androgen deprivation therapy or matching placebo + androgen deprivation therapy. The primary efficacy endpoints were radiographic progression‐free survival and overall survival. Secondary efficacy endpoints were time to cytotoxic chemotherapy, pain progression, chronic opioid use, and skeletal‐related events. Safety was also assessed. Results Of the 1052 patients included in the TITAN study, 51 (4.85%) were Japanese (apalutamide group, n = 28; placebo group, n = 23). In all, 81.8% of patients in the apalutamide and 71.8% in the placebo group did not experience radiographic progression or death, and the hazard ratio for radiographic progression‐free survival favored treatment with apalutamide (hazard ratio 0.712, 95% confidence interval 0.205–2.466; P = 0.59). At 24 months, 85.7% of patients in the apalutamide group and 81.5% in the placebo group were alive, and the hazard ratio for overall survival favored apalutamide (hazard ratio 0.840, 95% confidence interval 0.210–3.361; P = 0.805). In the interim analysis, the median radiographic progression‐free survival and overall survival were not reached in the apalutamide group and time to cytotoxic chemotherapy was delayed following apalutamide treatment. The safety profile of apalutamide in the Japanese subpopulation was comparable with that of the global population, except for skin rash. Conclusions The results of the present analyses suggest that apalutamide + androgen deprivation therapy in Japanese patients had favorable efficacy compared with androgen deprivation therapy alone, and these findings are comparable to those in the overall population. Apalutamide + androgen deprivation therapy can be considered as one of the therapeutic options for a broad spectrum of metastatic castration‐sensitive prostate cancer regardless of prior treatment and disease extent in Japanese patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
可爱的函函应助缘字诀采纳,获得10
1秒前
7秒前
啊哈发布了新的文献求助10
12秒前
12秒前
shain完成签到,获得积分10
12秒前
31秒前
星辰大海应助科研通管家采纳,获得10
33秒前
今后应助啊哈采纳,获得10
35秒前
mumu完成签到 ,获得积分10
36秒前
机智若云完成签到,获得积分10
43秒前
宋忘幽发布了新的文献求助10
1分钟前
星辰大海应助皮皮团采纳,获得10
1分钟前
1分钟前
iwaking发布了新的文献求助10
1分钟前
七宝完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
七宝关注了科研通微信公众号
1分钟前
1分钟前
1分钟前
曾瀚宇完成签到,获得积分10
1分钟前
ykswz99发布了新的文献求助30
1分钟前
1分钟前
1分钟前
李健应助含糊的万宝路采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
大模型应助科研通管家采纳,获得10
2分钟前
2分钟前
3分钟前
汉德萌多林完成签到,获得积分10
3分钟前
缘字诀完成签到,获得积分10
3分钟前
3分钟前
www发布了新的文献求助10
3分钟前
3分钟前
tiantian发布了新的文献求助10
3分钟前
4分钟前
元世立发布了新的文献求助20
4分钟前
缘字诀关注了科研通微信公众号
4分钟前
所所应助tiantian采纳,获得10
4分钟前
tiantian完成签到,获得积分10
4分钟前
高分求助中
Востребованный временем 2500
Hopemont Capacity Assessment Interview manual and scoring guide 1000
Injection and Compression Molding Fundamentals 1000
Classics in Total Synthesis IV: New Targets, Strategies, Methods 1000
Mantids of the euro-mediterranean area 600
The Oxford Handbook of Educational Psychology 600
Mantodea of the World: Species Catalog Andrew M 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 内科学 物理 纳米技术 计算机科学 基因 遗传学 化学工程 复合材料 免疫学 物理化学 细胞生物学 催化作用 病理
热门帖子
关注 科研通微信公众号,转发送积分 3422860
求助须知:如何正确求助?哪些是违规求助? 3023243
关于积分的说明 8903870
捐赠科研通 2710629
什么是DOI,文献DOI怎么找? 1486626
科研通“疑难数据库(出版商)”最低求助积分说明 687127
邀请新用户注册赠送积分活动 682330